Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvelisib versus gemcitabine or bendamustine in relapsed/refractory nodal T-cell lymphoma with TFH phenotype
NL-OMON61009Phase 3Recruiting
- Sponsor
- Secura Bio
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of duvelisib, gemcitabine, bendamustine in T follicular helper cell lymphoma (TFHL), angioimmunoblastic T-cell lymphoma (AITL), follicular T-cell lymphoma (FTCL), T-cell lymphoma follicular helper (TFHL), sponsored by Secura Bio. Started Sep 2025; status: recruiting.
02
Drugs
duvelisibgemcitabinebendamustine
03
Conditions
T follicular helper cell lymphoma (TFHL)angioimmunoblastic T-cell lymphoma (AITL)follicular T-cell lymphoma (FTCL)T-cell lymphoma follicular helper (TFHL)
Beyond the preview
Go deeper on NL-OMON61009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61009.